EUVIMEDEUVIMED entdecken
Crossref

Challenges in implementation of molecular classification in early stage endometrial cancer—An NRG Oncology cooperative group mixed‐methods study

Elise M Wilson iD, Ruizhi Huang, Kristen D Jones, Ian S Hagemann iD, Sarah M Temkin iD, Jessica N McAlpine iD, Matthew A Powell, Maura M Kepper, Andrea R Hagemann

Cancer · 2025

DOI: 10.1002/cncr.35596 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Elise M Wilson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University in St Louis, St Louis, Missouri, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, DNA Mismatch Repair. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: NCI NIH HHS, Washington University in St Louis, Washington University in St. Louis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Professional guidelines recommend molecular profiling for mismatch repair (MMR), p53, and polymerase epsilon ( POLE ) status in endometrial cancer (EC). However, adoption in the United States has not been documented, and barriers to the implementation of testing have not been described.

Methods

In this mixed‐methods study, implementation science frameworks were used to develop a quantitative survey. Gynecologic oncologists, medical oncologists, radiation oncologists, and pathologists affiliated with NRG Oncology programs were contacted through snowball sampling and were surveyed during 2022–2023. A subset of respondents was interviewed. Statistical and thematic analyses were performed.

Results

At least 403 NRG Oncology‐affiliated providers were contacted for the survey, and 107 (26.6%) responded. Greater than 90% of respondents perceived POLE , MMR, and p53 status as important for clinical care. MMR and p53 tests were perceived as easy to obtain, but only 24.2% of respondents reported that POLE testing was moderately or very easy to obtain. Respondents from academic sites reported better access to molecular classification and perceived greater importance of molecular classification compared with respondents from community sites. In thematic analysis of 13 qualitative interviews, cost concerns were reported as large barriers to testing. Interviewees reported a desire for prospective data to guide treatment selection based on classification results.

Conclusions

Although integrating molecular classification into standard pathologic reporting is recommended, and clinicians perceive molecular profiling in early stage EC as important, survey respondents noted significant implementation barriers. Implementation challenges that differ between community oncology and academic practice settings were identified. Strategies to improve equitable access to molecular classification of early stage EC are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsDNA Mismatch RepairHumansFemaleDNA Polymerase IITumor Suppressor Protein p53Poly-ADP-Ribose Binding ProteinsSurveys and QuestionnairesUnited StatesNeoplasm StagingOncologistsImplementation Science

Stichwörter der Autor:innen

NRG Oncologyendometrial cancermixed methodsmolecular profilingpathology

Substanzen

DNA Polymerase IITumor Suppressor Protein p53Poly-ADP-Ribose Binding ProteinsPOLE protein, humanTP53 protein, human

Autor:innen und Institutionen

  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University in St Louis, St Louis, Missouri, USA.
  • Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, San Diego, California, USA.
  • The Advanced Health Data (AHEAD) Institute, St Louis University School of Medicine, St Louis, Missouri, USA.
  • Department of Pathology and Immunology, Washington University in St Louis, St Louis, Missouri, USA.
  • National Institutes of Health Office of Research on Womens Health, Bethesda, Maryland, USA.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Elise M Wilson, Ian S Hagemann, Sarah M Temkin, Jessica N McAlpine

Förderung

  • NCI NIH HHS
  • Washington University in St Louis
  • Washington University in St. Louis

Zitieren

APA

Wilson, E. M., Huang, R., Jones, K. D., Hagemann, I. S., Temkin, S. M., McAlpine, J. N., Powell, M. A., Kepper, M. M., & Hagemann, A. R. (2025). Challenges in implementation of molecular classification in early stage endometrial cancer—An NRG Oncology cooperative group mixed‐methods study. Cancer. https://doi.org/10.1002/cncr.35596

Vancouver

Wilson EM, Huang R, Jones KD, Hagemann IS, Temkin SM, McAlpine JN, et al. Challenges in implementation of molecular classification in early stage endometrial cancer—An NRG Oncology cooperative group mixed‐methods study. Cancer. 2025. doi:10.1002/cncr.35596

BibTeX
@article{Wilson2025,
  author = {Wilson, Elise M and Huang, Ruizhi and Jones, Kristen D and Hagemann, Ian S and Temkin, Sarah M and McAlpine, Jessica N and Powell, Matthew A and Kepper, Maura M and Hagemann, Andrea R},
  title = {Challenges in implementation of molecular classification in early stage endometrial cancer—An NRG Oncology cooperative group mixed‐methods study},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35596}
}
Kostenlos starten →